我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 Astellas Pharma, Inc.
相关临床试验
13
12 进行中
药物批准
26
批准总数
监管机构
1
监管机构数
成立时间
N/A
进行中（未招募）
12
92.3%
已完成
7.7%
FDA
Food and Drug Administration
- The FDA issued a black box warning for fezolinetant (Veozah) due to rare but serious liver injury risks associated with the drug. - The warning advises regular liver blood testing for women taking Veozah to monitor and mitigate potential liver damage. - Fezolinetant is a non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) of menopause, approved by the FDA in 2023. - The FDA recommends monthly liver function tests for the first 3 months, then at 6 and 9 months, and to discontinue use if liver damage signs appear.
